Navigation Links
UVIDEM in Medical News

IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives

IRVINE, Calif., Dec. 31 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI ) today announced that as part of the Company's recent decision to evaluate strategic alternatives, the Company initiated discussions with sanofi-aventis. Following this, sanofi-aventis has notified the Company o...

IDM Pharma Reports First Quarter Financial Results

...ollaboration agreement with sanofi-aventis for the uvidem program. As a result of sanofi-aventis' decision to terminate its participation in the uvidem development program in December 2007, no further such revenues related to uvidem were recognized after the first quarter of 2008. ...

IDM Pharma Reports First Quarter Financial Results

... a result of sanofi-aventis' decision to terminate its participation in the uvidem development program in December 2007, no further such revenues related to uvidem will be recognized after this quarter. Research and development (R&D) exp...

IDM Pharma Reports 2007 Financial Results

...ult of the decision by sanofi-aventis to terminate its participation in the uvidem development program in December 2007. Cash and cash equivalents was $28.4 m...fi-aventis' decision in December 2007 to terminate its participation in the uvidem development program. Interest income increased to $0.4 million for the th...

IDM Pharma Reports Third Quarter 2007 Financial Results

...due to an increase in development costs related to uvidem clinical trials, which are reimbursed by sanofi-av...due to an increase in development costs related to uvidem clinical trials, which are reimbursed by sanofi-av...6. The spending related to clinical development of uvidem and clinical development, regulatory filings and m...

IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial

... IDM Pharma, Inc. today presented preliminary results from a Phase II uvidem (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The results showed that uvidem was well tolerated with evidence of efficacy and induction of immune respon...
UVIDEM in Medical Technology

IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company

...Updates UVIDEM(R) The next planned step in the uvidem development program is a Phase 2, open-label, randomized study of uvidem designed to evaluate patients with in-transient or...elanoma in the next 60 days. Patients will receive uvidem or...

IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients

...ated results showed that the investigational agent uvidem showed evidence of clinical activity and induction...recognized antigens after vaccination with uvidem were gp100 and MAGE. -- uvidem was well tolerated with only one possibly related ...

IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting

...annual meeting in Chicago on June 1-5 2007. uvidem presentation details: -- "Clinical and immu...gned to assess the safety and clinical activity of uvidem in patients with stage III or IV melanoma with mea...atient enrolled in March 2006. About UVIDEM(R) uvidem is a therapeutic specific immunostimulant develope...

IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial

... - Results show uvidem was well-tolerated with signs of durable disease c...inical trial (DC-MEL-202). The results showed that uvidem was well tolerated with evidence of efficacy and i...arance of anti-TAA specific CD8+ T cells. -- uvidem was well tolerated with toxicity limited to mild e...
UVIDEM in Biological Technology

IDM Pharma Reports 2008 Financial Results

...is' decision to terminate its participation in the uvidem development program in December 2007, we will not ... reduction in spending on MEPACT (mifamurtide) and uvidem development, as well as reductions associated with...ecember 2007 to terminate its participation in the uvidem development program. The $3.5 million includes $3...

IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development

...ical experience to IDM Pharma and will lead the regulatory and clinical strategy for L-MTP-PE and the development of the Company's pipeline, including uvidem and IDM-2101. He joins IDM Pharma from Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where...
Other Tags
(Date:3/4/2015)... March 04, 2015 Rocket Builders’ “Ready ... Columbian companies that have the best prospect for growth ... when we choose the Ready to Rocket companies, we ... technical innovation with market opportunity. Prizm Media Inc. is ... right customers at the right time,” said Reg Nordman, ...
(Date:3/4/2015)... Jose, CA (PRWEB) March 04, 2015 ... produced by companies whose management forgot – or ignored ... potential value: Validate the market based on physician input ... seen companies – more specifically, founders – become so ... answer the key question: Will physicians use the device?” ...
(Date:3/3/2015)... March 04, 2015 MED-Ed ... design and construction event for New England, April ... announced key building envelope related workshops. Sessions offer ... Workshops include: , Curtain Walls for Labs ... health care and laboratory facilities are often required ...
(Date:3/3/2015)... Anik Singal's Profit Academy - a ... has become the talk of the town throughout ... the course's general release has garnered the attention ... to review the program's content and publish an ... keys to success with Internet marketing is having ...
(Date:3/3/2015)... 2015 NOVAtime Technology, Inc. ( ... and Attendance / Workforce Management solutions, announced that ... SaaS Workforce Management / Time and Attendance ... , Since 2004, Innovative Services’ mission has ... the best quality of life. The company is ...
Breaking Medicine News(10 mins):Health News:Healthcare Lead Generation Leader Prizm Media Inc. is “Ready to Rocket” 2Health News:Healthcare Lead Generation Leader Prizm Media Inc. is “Ready to Rocket” 3Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 3Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 2Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 3Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 4Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 5Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 6Health News:Anik Singal's Profit Academy - Review Of New IM Training Program Released 2Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 2Health News:Innovative Services, Inc. Successfully Migrates to Cloud-Based NOVAtime Workforce Management Solution to Support Growth and Improve Payroll Processing Time 3
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) ... Global Market Overview" report to their offering. , ... ensure that an individual is who she/he is claiming to ... of a person,s unique physical characteristics, such as fingerprint, hand ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
Other Contents